# Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

> **NCT06914687** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 30 (estimated)

## Conditions studied

- Gastric Adenocarcinoma
- Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
- Peritoneal Metastasis

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** S-1
- **DRUG:** Oxaliplatin
- **DRUG:** Docetaxel
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT06914687
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03-30
- **Primary completion:** 2028-04-01
- **Final completion:** 2028-04-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06914687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06914687, "Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06914687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*